Recruiting
Phase 2

Atovaquone

Sponsor:

Emory University

Code:

NCT05998135

Conditions

Ovarian High Grade Serous Adenocarcinoma

Platinum-Resistant Ovarian Carcinoma

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Atovaquone

Biopsy

Computed Tomography

Paracentesis

Study Details

Brief summary:

This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia. Giving atovaquone may be effective in treating platinum-resistant ovarian cancer and result in improved outcomes compared to standard chemotherapy regimens.

Conditions

Ovarian High Grade Serous Adenocarcinoma

Platinum-Resistant Ovarian Carcinoma

Study ID

NCT05998135

Start date

Nov 9, 2023

Status verified date

Sep, 2025

Completion date

Jun 30, 2027

Anticipated

Primary completion date

Jun 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy
  • Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • There will be no limitations on number of prior lines of therapy
  • Trial is open to non-English speaking patients
  • Trial is open to patients referred from community practice

Exclusion Criteria:

  • Patients who are < 18 years old
  • Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)
  • Patients who are incarcerated
  • Patients who are unable to provide consent / lack decision-making capacity

Study Design

Enrollment

28 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Treatment (atovaquone)

Patients receive atovaquone PO on study. Patients also undergo CT and biopsy or paracentesis throughout the study.

Interventions

Atovaquone

Given PO

Biopsy

Undergo biopsy

Computed Tomography

Undergo CT

Paracentesis

Undergo paracentesis

Primary outcome measure

  • Progression free survival (PFS) [ Time Frame: From initiation of atovaquone to progression or death, assessed up to 1 year ]

Central Contacts and Locations

Central contacts

Namita Khanna, MD, MSPH

404-778-3401namita.khanna@emory.edu

Locations

Emory University Hospital/Winship Cancer Institute

Recruiting

Atlanta, Georgia, United States, 30322

Contacts

Nina Kimball

404-778-8145nina.cathleen.dobbs.kimball@emory.edu

Maisey S Ratcliffe

404-778-3449maisey.shannon.ratcliffe@emory.edu

Principal Investigator:

Namita Khanna, MD, MSPH

More Information

Sponsor

Emory University

Last update posted

Sep 11, 2025

Last verified

Sep, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Emory University on 2025-09-11.